China Pharma Holdings, Inc. (CPHI)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
HIGH DILUTION RISKDilution score: 68/100 (HIGH), 1.7 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 0.16% of float, squeeze risk: LOW
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- China Pharma Holdings, Inc. Announces Closing of $5.0 Million Registered Direct Offering
- China Pharma Announces Pricing of $5 Million Registered Direct Offering
- China Pharma Holdings, Inc. Comments on Unusual Market Activity
- China Pharma Holdings, Inc. States It Knows of No Events That Could Have Caused Unusual Market Activity
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
- SEC 8-K 8-K - Current report
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- Imaging-guided shortened interpregnancy interval following myomectomy in China: protocol for a multicentre prospective randomised controlled trial. — BMJ Open 2026 Oct 7 PMID 42843867
- Evaluating the effect of spectacle correction for refractive errors and presbyopia on cognitive function in rural older adults in China: protocol for a randomised, parallel-group, superiority trial. — BMJ Open 2026 Oct 7 PMID 42843862
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for China Pharma Holdings, Inc..
Full CPHI Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.